- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Gland Pharma Limited has received approval from the U.S. Food and Drug Administration for its Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill). This product is bioequivalent to Xalatan®, which addresses high eye pressure in patients with open-angle glaucoma or ocular hypertension. The company anticipates launching this product through its marketing partners in FY25. According to IQVIA, Latanoprost had U.S. sales of approximately USD 111.6 million for the twelve months ending December 2023. This approval reinforces Gland Pharma's position in the ophthalmic segment and presents significant revenue potential as the company expands its product offerings in the U.S. market.